

**1 The benefit of hypothermic targeted temperature management decreases when**  
**2 post-arrest care improves**

3

4 Wei-Ting Chen, MD<sup>1</sup>; Yu-Tzu Tien, MD<sup>1</sup>; Chien-Hua Huang, MD, PhD<sup>1</sup>; Chih-Hung  
 5 Wang, MD, PhD<sup>1</sup>; Wei-Tien Chang, MD, PhD<sup>1</sup>; Hooi-Nee Ong, MD<sup>1</sup>; Wen-Jone  
 6 Chen, MD, PhD<sup>1,2,3</sup>; Min-Shan Tsai, MD, PhD<sup>1</sup>

7

8 <sup>1</sup>Department of Emergency Medicine, National Taiwan University Medical College  
 9 and Hospital, Taipei, Taiwan

10 <sup>2</sup>Department of Internal Medicine (Cardiology division), National Taiwan University  
 11 Medical College and Hospital, Taipei, Taiwan

12 <sup>3</sup>Department of Internal Medicine, Min-Shen General Hospital, Taoyuan, Taiwan

13

**14 Name and address of Corresponding authors:**

15 Min-Shan Tsai, MD, PhD

16 Department of Emergency Medicine, National Taiwan University Hospital

17 No. 7, Chung-Shan S. Road, Taipei, Taiwan 100

18 E-mail: [mshanmshan@gmail.com](mailto:mshanmshan@gmail.com)

19

20 The study was performed in National Taiwan University Hospital.

21

**22 Short running title:** Less TTM benefit when post-arrest care improves

23

**24 Word count of Abstract:** 341 words

**25 Word count:** 2757 words

# 1    **Abstract**

## 2    **Background:**

3        Several clinical trials and cohort studies in the past two decades have  
4        demonstrated inconsistent results regarding survival and neurologic recovery benefits  
5        for patients undergoing targeted temperature management (TTM) at 33°C as  
6        compared to those undergoing TTM at 36°C or normothermia. Whether the improved  
7        quality of post-arrest care over time contributes to diminishing benefit of TTM at  
8        33°C remains un-investigated.

## 9    **Methods:**

10       There were 1,809 adult non-traumatic cardiac arrest survivors during 2011-2020.  
11       After excluding patients with pre-arrest poor conscious level defined as  
12       Glasgow-Pittsburgh Cerebral Performance Category (CPC) >2 (n=258), patients who  
13       regained clear consciousness after return of spontaneous circulation (ROSC) (n=300),  
14       patients with active bleeding or intracranial hemorrhage (n=48) and patients who  
15       underwent TTM of 36°C due to unstable hemodynamic (n=11), a total of 1,192  
16       eligible candidates for TTM of 33°C were finally enrolled and classified into Period 1  
17       (during 2011-2015, n = 449) and Period 2 (during 2016-2020, n = 693).

## 18   **Results:**

19       Patients in Period 2 received more diagnostics procedures and specific therapies

than those in Period 1. The proportion of patients with good neurological recovery at hospital discharge in Period 2 is significantly higher than that in Period 1 (21.4% vs. 14.0%, adjusted odds ratio [aOR] 1.60, 95% confidence interval [CI] 1.14-2.26). TTM was beneficial for the outcomes in both Period 1 and 2, with patients in Period 1 having higher chances of survival and good neurological outcome than those in Period 2 (survival: aOR 5.66, 95% CI 3.49-9.18 vs. aOR 2.91, 95% CI 1.98-4.28; good neurological recovery: aOR 3.92, 95% CI 2.12-7.25 vs. aOR 2.19, 95% CI 1.43-3.34). Among patients with low-risk and medium-risk severity of illness, TTM benefited survival and neurological outcomes, regardless of time period. But the chance of beneficial outcomes decreased consistently from Period 1 to Period 2.

## Conclusion

Among cardiac arrest survivors, improvement in the quality of post-cardiac arrest care over time is associated with better neurological recovery. TTM remains beneficial for survival and neurological outcomes following cardiac arrest, regardless of the time period. However, the benefit of TTM may diminish when post-cardiac arrest care improves.

**Keywords:** Cardiac arrest; neurological recovery; targeted temperature management; 33°C; protocolization

# 1 Background

2 In recent decade, the dispute whether preventing fever following return of  
3 spontaneous circulation (ROSC) rather than reducing body temperature to 33°C was  
4 enough to alleviate post-arrest brain injury has been raised, since the TTM and TTM2  
5 trials demonstrated no difference in survival and neurological outcomes between  
6 patients underwent TTM of 33°C vs. 36°C,<sup>1</sup> or vs. <37.8°C,<sup>2</sup>. However, several  
7 retrospective cohort studies have shown less protocol compliance<sup>3</sup> and more fever  
8 during the early post-arrest period,<sup>3,4</sup> and thus worse survival and neurological  
9 recovery in patients underwent targeted temperature management (TTM) of 36°C.<sup>4-6</sup>  
10 Moreover, the HYPERION trial demonstrated better neurological recovery in TTM of  
11 33°C than normothermia among patients with non-shockable rhythm.<sup>7</sup> The severity of  
12 post-cardiac arrest syndrome was proposed to account for the discrepancies between  
13 these studies. Better outcomes were observed when temperature was targeted at 33°C  
14 in the patients with moderate-severity.<sup>8,9</sup>

15 In addition to illness severity, the benefit of protocolized post-arrest care in the  
16 trials may also attribute to the insignificant difference between hypothermia and  
17 normothermia. The importance of post-cardiac arrest care began to be emphasized  
18 since 2010, and a multidisciplinary, systemic approach of care was proposed,  
19 including optimization of ventilation and hemodynamics, neurologic management,

glycemic control, TTM and immediate coronary revascularization.<sup>10,11</sup> Our previous study demonstrated that these practices help improve the quality of care in patients without TTM.<sup>12</sup> However, whether benefit of therapeutic hypothermia over no temperature management decreases along with the improved post-arrest care remains uninvestigated. Before the launch of the 2015 American Heart Association (AHA) guidelines, the National Taiwan University Hospital (NTUH) only used the TTM protocol with a target temperature of 33°C. Since 2016 January, the NTUH protocol has been revised to subject stable patients to TTM at 33°C while only a few patients with unstable hemodynamics or arrhythmia are treated at 36°C. The aim of this study was to examine the benefit of hypothermic TTM at 33°C on survival and favorable neurologic recovery during the time period from 2010 to 2020, in the context of the improvements of post-arrest care.

# 1    **Methods**

## 2    **Demographics/Epidemiology**

3        This retrospective cohort study was conducted at National Taiwan University  
4    Hospital, a 2500-bed tertiary medical center located in Taipei City with 110,000  
5    annual emergency department visits<sup>13</sup>. The Institutional Review Board of NTUH  
6    approved the study(202111079RINA) and waived participant consent.

## 7    **Participants Selection**

8        The study enrolled 1,809 adult, non-traumatic cardiac arrest victims with  
9    successful resuscitation between January 2011 and December 2020 in the ED of  
10   NTUH. Patients were excluded if they had a pre-arrest poor consciousness level,  
11   defined as Glasgow-Pittsburgh Cerebral Performance Category (CPC)>2 (n=258), had  
12   regained clear consciousness within 3 hours after ROSC (n=300), had massive  
13   bleeding or intracranial hemorrhage at ROSC (n=48), and who underwent TTM with  
14   a target temperature of 36°C due to unstable hemodynamics (n=11). A total of 1,192  
15   eligible candidates for TTM with target temperature at 33°C were finally enrolled in  
16   the current study. When further classified by the AHA guidelines revised in Dec 2015,  
17   449 patients with an index cardiac arrest between 2011-2015 were further classified as  
18   “Period 1”, and 693 patients with an index cardiac arrest between 2016-2020 were  
19   classified as “Period 2” (Figure 1).

## 1 **TTM Protocol of NTUH**

2 NTUH is the first hospital in Taiwan to introduce TTM for cardiac arrest  
 3 survivors, and has established a protocol for TTM since 2003. After the application of  
 4 cooling devices was approved by the Taiwan Ministry of Health and Welfare in 2005,  
 5 the first patient underwent TTM in 2006. The protocols for post-cardiac arrest care,  
 6 including TTM, were updated sequentially in alignment with the 2010, 2015 and 2020  
 7 AHA guidelines.<sup>10,14,15</sup> Before the launch of 2020 AHA guideline, the cardiac arrest  
 8 survivors underwent TTM at 33°C except for those with unstable hemodynamic even  
 9 with more than 2 inotropes support in the early post-arrest period and those with  
 10 massive bleeding or intracranial hemorrhage after ROSC. Cold saline and cooling  
 11 devices with auto-feedback were used to reduce patients' body temperatures to the  
 12 target temperature of 33°C within 4–6 hours after ROSC, maintain target temperature  
 13 for 24 hours, and rewarm patients at the rate of 0.25°C per hour until 36°C was  
 14 achieved. Temperature management was continued for another 24 hours after  
 15 rewarming to avoid fever<sup>13</sup>.

## 16 **Data Collection and Variables Definition**

17 The primary data set was obtained from the hospital medical record data  
 18 repository and included demographic information, past medical history, prehospital  
 19 arrest events, cardiac arrest details, post-arrest management, laboratory examinations,

1 and disposition. This study followed Strengthening the Reporting of Observational  
2 Studies in Epidemiology (STROBE) reporting guidelines.<sup>16</sup>

3 Patients with cardiac arrest were considered as either those with out-of-hospital  
4 cardiac arrest (OHCA), with in-hospital cardiac arrest (IHCA) after triage, or those  
5 who achieved ROSC before being transferred from another hospital. Cardiogenic  
6 arrest was recorded when ischemic heart disease, structural heart disease, heart failure,  
7 or arrhythmia without an electrolyte imbalance was considered the cause of arrest.  
8 The causes of cardiac arrest were determined by the responsible primary care  
9 physicians, who were blinded to the current study. Repeated CPR was defined as  
10 another episode of arrest within one hour after initial ROSC.

11 Overall cardiac arrest severity was assigned using the simplified Cardiac Arrest  
12 Hospital Prognosis (sCAHP) score as our previous publication, which excluded the  
13 no-flow interval data with similar predictive accuracy as the original score in an East  
14 Asian population.<sup>17</sup> The illness severity ( $\leq 150$  as low-risk, 151-199 as medium-risk,  
15 and  $\geq 200$  as high-risk) was determined by using the method with a scheme that used  
16 significant F-values for cut-off points.<sup>18</sup> The performance of illness severity  
17 categorized by the sCAHP score (our data) and the CAHP score (Sudden Death  
18 Expertise Center registry, Paris, France)<sup>19</sup> is shown in Supplementary Table 1.

19 During the early post-arrest period, electrocardiogram (ECG), echocardiography



1 and cerebral computed tomography after ROSC were recorded. Emergent coronary  
2 angiography (CAG) was recorded when indicated patients underwent CAG within 24  
3 hours after ROSC. Extracorporeal membrane oxygenation (ECMO) was recorded  
4 when applied as indicated during index resuscitation. Fever ( $\geq 38.3^{\circ}\text{C}$ ), infection  
5 workup, electroencephalogram (EEG) and anti-epileptic drugs (AED) use during first  
6 3 days after ROSC were documented.

## 7 **Outcome Measures**

8 The primary outcome was favorable neurological recovery at hospital discharge,  
9 defined as a CPC of 1 (good recovery) or 2 (moderate disability). The secondary  
10 outcomes include survival at hospital discharge, as well as at 3-month and 1-year  
11 follow-ups. CPC at hospital discharge was evaluated by primary care physicians who  
12 were blinded to the current study.

## 13 **Patient and public involvement**

14 The patients and public were not involved in the creation of the study design,  
15 recruitment or statistical analysis. Patients were not consulted to develop patient  
16 relevant outcomes or interpret the results. Patients were not invited to contribute to the  
17 writing or editing of this manuscript.

## 18 **Statistical Analysis**

19 Descriptive statistics were presented as frequencies for categorical variables and

1 the median with interquartile ranges for continuous variables. For 2 group comparison,  
2 Fisher's exact or Pearson's chi-squared test for categorical variables, and the  
3 Mann-Whitney U test for continuous variables were used. Multiple imputation  
4 (Markov Chain Monte Carlo) was used for missing data of laboratory examinations.  
5 Multivariable logistic regression models were used to examine the association  
6 between outcomes and time periods, and the benefit of hypothermic TTM over  
7 non-TTM on survival and good neurological recovery. All statistical analyses were  
8 performed using SPSS Statistics for Windows, version 16.0 (SPSS Inc., Chicago, IL,  
9 USA). Statistical significance was assessed using two-sided 95% confidence intervals  
10 (CI) and a  $p < 0.05$ .

11

12

13

14

15

16

17

18

19

1

2

### 3 **Results**

#### 4 **Period 1 vs. Period 2**

5 A comparison of the patient characteristics, cardiac arrest events, and laboratory  
6 examinations between the two time periods is presented in Table 1. As compared with  
7 Period 1, the proportion of coronary artery disease, arrhythmia, OHCA, witnessed  
8 collapse, initial shockable rhythm and bystander CPR were higher during Period 2. But  
9 the adrenaline dosage, systolic blood pressure at ROSC, PH and HCO<sub>3</sub> of blood gas  
10 were lower in patients during Period 2 than Period 1. Patients in Period 2 had higher  
11 sCAHP severity and APACHE II scores than those in Period 1. More patients in Period  
12 2 received echocardiography, brain CT, emergent CAG, TTM and inotrope support  
13 following ROSC as well as EEG and AEDs within 3 days after cardiac arrest. Patients  
14 in Period 1 had longer duration from cooling to target temperature and greater highest  
15 body temperature when compared with those in Period 2. Increased active withdrawal  
16 was also noted in Period 2 (Table 2).

17 A representation of the proportion of patients that did not survive to hospital  
18 discharge, with poor CPC, and with good CPC between the two time periods can be  
19 seen in Figure 2. Mortality rates are comparable with 71.1% in Period 1 and 72.2% in

1 Period 2. The chance of patients with good neurological recovery at ICU discharge  
2 (adjusted OR [aOR] 1.79, 95% CI=1.27-2.51) and hospital discharge (aOR 1.60, 95%  
3 CI=1.14-2.26) in Period 2 was significantly higher than in Period 1. There were no  
4 difference of 3-month and 1-year survival between Period 1 and Period 2 (Table 3).

#### 5 **Non-TTM vs. hypothermic TTM**

6 There were 374 patients receiving hypothermic TTM following ROSC classified  
7 as the TTM group and the rest 818 patients classified as the non-TTM group. A  
8 comparison of underlying characteristics, cardiac arrest events, and laboratory results  
9 between patients with and without TTM treatment are presented in Supplementary  
10 Table 2. The patients in the TTM group were younger than those in the non-TTM group  
11 and suffered from less pre-arrest co-morbidity, such as bed-ridden and malignancy.  
12 Compared with the non-TTM group, the TTM group had a higher proportion of patients  
13 with OHCA, initial shockable rhythm, prehospital CPR, prehospital ROSC and  
14 presumed cardiogenic arrest, but less percentage of repeated CPR and high-risk  
15 severity. Besides, the TTM group required a lower adrenaline dosage, and had lower  
16 APACHE II scores but higher heart rates, systolic blood pressures, hemoglobin and  
17 platelet concentrations than the non-TTM group. Supplementary Table 3 demonstrates  
18 better post-arrest care in the TTM group than the non-TTM group including more  
19 cardiovascular and cerebral evaluations, better adherence to ventilation and

1 hemodynamic recommendations, more infection workups, and early seizure detection  
2 and treatment. A comparison between the TTM and non-TTM groups in each time  
3 period is shown in Supplementary Tables 4 and 5.

4 Although significant interaction between time period and TTM was noted, both  
5 Period 2 and TTM remained associated with improved neurological recovery  
6 (Supplementary Table 6). Compared with the non-TTM group, patients who  
7 underwent TTM had better survival (aOR 3.67, 95% CI=2.73-4.93) and neurological  
8 outcome (aOR 2.71, 95% CI=1.92-3.82). TTM remained beneficial in both Period 1  
9 and Period 2, and the benefit of TTM over non-TTM in survival and neurological  
10 recovery was higher in Period 1 as compared to Period 2 (survival: aOR 5.66, 95%  
11 CI=3.49-9.18 vs. aOR 2.91, 95% CI=1.98-4.28; good neurological recovery: aOR  
12 3.92, 95% CI=2.12-7.25 vs. aOR 2.19, 95% CI=1.43-3.34). The enrolled patients  
13 were further stratified by sCAHP severity with 248 patients of low-risk severity, 547  
14 patients of medium-risk severity and 397 patients of high-risk severity, respectively.  
15 Among patients with low- and medium-risk severity, TTM benefited survival and  
16 neurological outcomes, regardless of time period. But the chance for good outcomes  
17 consistently decreased from Period 1 to Period 2 in both low- and medium-risk  
18 subgroups. There was no significant benefit of TTM in patients with high-risk severity  
19 (Figure 3).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

## Discussion

In this study, Period 2 had better post-arrest care than Period 1, and the neurological recovery improved significantly in Period 2. TTM were beneficial for survival and neurological outcomes among cardiac arrest patients in both time periods, especially in those with low- and medium-risk severity; however, its benefit diminished over time.

To alleviate post-cardiac arrest syndrome, bundle care focused on identifying the cause of arrest and preventing recurrence, providing ventilation to minimize lung injury, optimizing cardiovascular function, early detecting and treating post-arrest seizure, reducing risk of multiorgan injury, and controlling body temperature has been suggested by AHA guidelines since 2010.<sup>10</sup> In the current study, patients in Period 2 had increased diagnostics procedures performed and specific therapies given for timely and appropriate management than those in Period 1. Although both short-term and long-term survival are comparable between Period 1 and Period 2, the benefit of improved post-cardiac arrest care might be reflected in more favorable neurological recovery in Period 2. The increased active withdrawal for patients with potentially poor neurological outcome and “do-not-attempt resuscitation” after ROSC in Period 2 may account for the insignificant difference in survival at hospital discharge between

1 these 2 periods. Besides, the finding that approximately half of the patients discharged  
2 from the hospital died within 3 months emphasizes the importance of rehabilitation  
3 and health care after hospital discharge. Further studies are warrant to investigate the  
4 causes of death after hospital discharge.

5 In our current study, TTM at 33°C remains beneficial in both time periods. The  
6 benefits of hypothermic TTM over non-TTM decreased in Period 2 in all enrolled  
7 patients as well as subgroups stratified by illness severity. The improved post-arrest  
8 care may account for this finding since the interventions were in place for all  
9 successfully resuscitated victims, regardless of TTM treatments. This finding also  
10 raises another important question—*Does the benefit of TTM on outcomes truly result*  
11 *from TTM or the protocolized care established along with TTM?* Laboratory animal  
12 studies displayed that therapeutic hypothermia at 32-33 °C ameliorated myocardial  
13 injury and brain damage after ischaemia/reperfusion injury, and thus, improved  
14 survival and neurological recovery.<sup>20,21</sup> However, clinical trials showed inconsistent  
15 results concerning the benefit of TTM at 33 °C as compared with normothermia or no  
16 temperature control.<sup>1,2,7,22,23</sup>

17 Bernard et al. , HACA and HYPERION trials demonstrated improved survival  
18 and neurological outcomes in patients underwent therapeutic hypothermia at 33  
19 °C.<sup>7,22,23</sup> However, the TTM trial demonstrated no difference in survival and

1 neurological recovery between patients receiving TTM at 33 °C and 36 °C,  
2 emphasizing the importance of temperature control rather than the low target  
3 temperature.<sup>1</sup> In 2021, the TTM2 trial once again demonstrated no outcome benefit in  
4 patients receiving TTM at 33 °C compared with those <37.8 °C, implying that  
5 aggressively preventing fever may be the main determinant factor.<sup>2</sup> The evolution of  
6 post-cardiac arrest care within the two decades may account for the inconsistent  
7 results of these trials. Similar situation can be observed in the care of sepsis. The  
8 ARISE trial failed to show the benefit of early goal-directed therapy(EGDT) in  
9 reducing mortality, and the improvement of medical care quality along with the  
10 protocol establishment was proposed as a reason for comparable outcomes in the  
11 EGDT and control groups.<sup>24</sup> The protocolized approaches usually facilitate medical  
12 teams to provide more consistent care and overcome barriers.<sup>25,26</sup> Our results supported  
13 the hypothesis that the improved quality of post-arrest care would diminish the benefit  
14 of TTM on outcomes. Several retrospective cohort studies also demonstrated worse  
15 outcomes in patients with less adherence to protocols of temperature control.<sup>3-5</sup>  
16 Similar diminished difference between intervention and standard groups can also be  
17 observed in the Box trial: no outcome difference between different blood-pressure  
18 targets and different oxygen targets in cardiac arrest survivors.<sup>27,28</sup>

## 19 **Limitation**



1        This study had several limitations. First, due to the its retrospective nature,  
2        selection bias was unavoidable, and unidentified confounding factors or improvement  
3        of post-arrest care might be present. Second, the post-cardiac arrest care in the TTM  
4        group were better than that in the non-TTM group. The frequency of CT, emergent  
5        CAG and EEG of the TTM group were comparable with those in published  
6        studies.<sup>2,5,9</sup> However, there is a lack of studies reporting the quality of post-arrest care  
7        in patients without TTM and we cannot compare our results with others. Nevertheless,  
8        our results indicated that much room for us to improve the care quality in patients  
9        without TTM. And the care discrepancy between the TTM and non-TTM groups  
10       might be the primary source of the TTM benefit as we hypothesized. Third, the  
11       reasons for patients not undergoing TTM were not recorded. The socioeconomic status  
12       of these patients, which might affect willingness to undergo TTM, was also not  
13       considered. However, standard ICU and post-arrest care are covered by National Health  
14       Insurance in Taiwan, and TTM was incorporated into the coverage in October 2015.  
15       Additionally, the neurological function was not recorded during the follow-up after  
16       hospital discharge. Finally, our study investigated a homogenous Asian population,  
17       and great caution should be exercised when attempting to extrapolate our results to  
18       other races.

19

# 1 **Conclusion**

2       Among cardiac arrest survivors, the improved quality of post-cardiac arrest care  
3 over time is associated with better neurological recovery. Regardless of the time  
4 periods, hypothermic TTM remained beneficial to survival and neurological outcomes  
5 following cardiac arrest. However, benefit of TTM over non-TTM might be  
6 diminished along with improvement in post-cardiac arrest care.

7

# 8 **Declarations**

9 Ethics approval and consent to participate:

10       This retrospective cohort study was approved by the Institutional Review Board  
11 of NTUH (202111079RINA) and waived participant consent.

12 Consent for publication: not applicable

13 Availability of data and material:

14       The data sets used and analysed during the current study are available from the  
15 corresponding author on reasonable request

16 Competing interests: The authors declare that they have no competing interests.

17 Funding: not applicable

18 Authors' contributions:

19       All authors contributed to the study conception and design. Material

1 preparation and data collection were performed by CWT and OHN. The  
 2 analysis was performed by TMS, TYT and WCH. The first draft of the  
 3 manuscript was written by CWT. TMS, HCH and CWJ revised it critically for  
 4 important intellectual content.

## 5 Acknowledgements

6 The authors would like to express their thanks to the staff of National Taiwan  
 7 University Hospital-Statistical Consulting Unit (NTUH-SCU) for statistical  
 8 consultation.

9

10

## 1     **References**

- 2     1.     Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, Horn J,  
3           Hovdenes J, Kjaergaard J, Kuiper M, et al. Targeted temperature management  
4           at 33 degrees C versus 36 degrees C after cardiac arrest. *N Engl J Med*.  
5           2013;369:2197-2206. doi: 10.1056/NEJMoa1310519
- 6     2.     Dankiewicz J, Cronberg T, Lilja G, Jakobsen JC, Levin H, Ullen S, Rylander C,  
7           Wise MP, Oddo M, Cariou A, et al. Hypothermia versus Normothermia after  
8           Out-of-Hospital Cardiac Arrest. *N Engl J Med*. 2021;384:2283-2294. doi:  
9           10.1056/NEJMoa2100591
- 10    3.     Bray JE, Stub D, Bloom JE, Segan L, Mitra B, Smith K, Finn J, Bernard S.  
11           Changing target temperature from 33 degrees C to 36 degrees C in the ICU  
12           management of out-of-hospital cardiac arrest: A before and after study.  
13           *Resuscitation*. 2017;113:39-43. doi: 10.1016/j.resuscitation.2017.01.016
- 14    4.     Salter R, Bailey M, Bellomo R, Eastwood G, Goodwin A, Nielsen N, Pilcher D,  
15           Nichol A, Saxena M, Shehabi Y, et al. Changes in Temperature Management of  
16           Cardiac Arrest Patients Following Publication of the Target Temperature  
17           Management Trial. *Crit Care Med*. 2018;46:1722-1730. doi:  
18           10.1097/CCM.0000000000003339
- 19    5.     Johnson NJ, Danielson KR, Counts CR, Ruark K, Scruggs S, Hough CL, Maynard  
20           C, Sayre MR, Carlhom DJ. Targeted Temperature Management at 33 Versus 36  
21           Degrees: A Retrospective Cohort Study. *Crit Care Med*. 2020;48:362-369. doi:  
22           10.1097/CCM.0000000000004159
- 23    6.     Minini A, Annoni F, Peluso L, Bogossian EG, Creteur J, Taccone FS. Which  
24           Target Temperature for Post-Anoxic Brain Injury? A Systematic Review from  
25           "Real Life" Studies. *Brain Sci*. 2021;11. doi: 10.3390/brainsci11020186
- 26    7.     Lascarrou JB, Merdji H, Le Gouge A, Colin G, Grillet G, Girardie P, Coupez E,  
27           Dequin PF, Cariou A, Boulain T, et al. Targeted Temperature Management for  
28           Cardiac Arrest with Nonshockable Rhythm. *N Engl J Med*.  
29           2019;381:2327-2337. doi: 10.1056/NEJMoa1906661
- 30    8.     Callaway CW, Coppler PJ, Faro J, Puyana JS, Solanki P, Dezfulian C, Doshi AA,  
31           Elmer J, Frisch A, Guyette FX, et al. Association of Initial Illness Severity and  
32           Outcomes After Cardiac Arrest With Targeted Temperature Management at  
33           36 degrees C or 33 degrees C. *JAMA Netw Open*. 2020;3:e208215. doi:  
34           10.1001/jamanetworkopen.2020.8215
- 35    9.     Nishikimi M, Ogura T, Nishida K, Hayashida K, Emoto R, Matsui S, Matsuda N,  
36           Iwami T. Outcome Related to Level of Targeted Temperature Management in  
37           Postcardiac Arrest Syndrome of Low, Moderate, and High Severities: A

- 1            Nationwide Multicenter Prospective Registry. *Crit Care Med.*  
2            2021;49:e741-e750. doi: 10.1097/CCM.0000000000005025
- 3    10.    Peberdy MA, Callaway CW, Neumar RW, Geocadin RG, Zimmerman JL,  
4            Donnino M, Gabrielli A, Silvers SM, Zaritsky AL, Merchant R, et al. Part 9:  
5            post-cardiac arrest care: 2010 American Heart Association Guidelines for  
6            Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.  
7            *Circulation.* 2010;122:S768-786. doi: 10.1161/circulationaha.110.971002
- 8    11.    Chen WT, Tsai MS, Huang CH, Chang WT, Chen WJ. Protocolized Post-Cardiac  
9            Arrest Care with Targeted Temperature Management. *Acta Cardiol Sin.*  
10           2022;38:391-399. doi: 10.6515/ACS.202205\_38(3).20211220A
- 11   12.    Ling DA HC, Chen WJ, Chuang PY, Chang WT, Sung CW, Chen WT, Ong HN, Tsai  
12           MS. Impact of protocolized postarrest care with targeted temperature  
13           management on the outcomes of cardiac arrest survivors without  
14           temperature management. *Ann Med.* 2022;54:63-70.
- 15   13.    Lin JJ, Huang CH, Chen WJ, Chuang PY, Chang WT, Chen WT, Tsai MS. Targeted  
16           temperature management and emergent coronary angiography are  
17           associated with improved outcomes in patients with prehospital return of  
18           spontaneous circulation. *J Formos Med Assoc.* 2020;119:1259-1266. doi:  
19           10.1016/j.jfma.2020.03.017
- 20   14.    Neumar RW, Shuster M, Callaway CW, Gent LM, Atkins DL, Bhanji F, Brooks SC,  
21           de Caen AR, Donnino MW, Ferrer JM, et al. Part 1: Executive Summary: 2015  
22           American Heart Association Guidelines Update for Cardiopulmonary  
23           Resuscitation and Emergency Cardiovascular Care. *Circulation.*  
24           2015;132:S315-367. doi: 10.1161/CIR.0000000000000252
- 25   15.    Panchal AR, Bartos JA, Cabañas JG, Donnino MW, Drennan IR, Hirsch KG,  
26           Kudenchuk PJ, Kurz MC, Lavonas EJ, Morley PT, et al. Part 3: Adult Basic and  
27           Advanced Life Support: 2020 American Heart Association Guidelines for  
28           Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.  
29           *Circulation.* 2020;142:S366-s468. doi: 10.1161/cir.0000000000000916
- 30   16.    Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ,  
31           Poole C, Schlesselman JJ, Egger M, Initiative S. Strengthening the Reporting of  
32           Observational Studies in Epidemiology (STROBE): explanation and elaboration.  
33           *International journal of surgery.* 2014;12:1500-1524. doi:  
34           10.1016/j.ijsu.2014.07.014
- 35   17.    Wang CH, Huang CH, Chang WT, Tsai MS, Yu PH, Wu YW, Chen WJ. Prognostic  
36           performance of simplified out-of-hospital cardiac arrest (OHCA) and cardiac  
37           arrest hospital prognosis (CAHP) scores in an East Asian population: A  
38           prospective cohort study. *Resuscitation.* 2019;137:133-139. doi:

- 10.1016/j.resuscitation.2019.02.015
18. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. *Pain*. 1995;61:277-284. doi: 10.1016/0304-3959(94)00178-H
19. Maupain C, Bougouin W, Lamhaut L, Deye N, Diehl JL, Geri G, Perier MC, Beganton F, Marijon E, Jouven X, et al. The CAHP (Cardiac Arrest Hospital Prognosis) score: a tool for risk stratification after out-of-hospital cardiac arrest. *Eur Heart J*. 2016;37:3222-3228. doi: 10.1093/eurheartj/ehv556
20. Tsai MS, Huang CH, Tsai CY, Chen HW, Cheng HJ, Hsu CY, Chang WT, Chen WJ. Combination of intravenous ascorbic acid administration and hypothermia after resuscitation improves myocardial function and survival in a ventricular fibrillation cardiac arrest model in the rat. *Acad Emerg Med*. 2014;21:257-265. doi: 10.1111/ace.12335
21. Huang CH, Tsai MS, Chiang CY, Su YJ, Wang TD, Chang WT, Chen HW, Chen WJ. Activation of mitochondrial STAT-3 and reduced mitochondria damage during hypothermia treatment for post-cardiac arrest myocardial dysfunction. *Basic Res Cardiol*. 2015;110:59. doi: 10.1007/s00395-015-0516-3
22. Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, Smith K. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. *N Engl J Med*. 2002;346:557-563. doi: 10.1056/NEJMoa003289
23. Group HaCAS. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. *New England Journal of Medicine*. 2002;346:549-556.
24. Investigators A, Group ACT, Peake SL, Delaney A, Bailey M, Bellomo R, Cameron PA, Cooper DJ, Higgins AM, Holdgate A, et al. Goal-directed resuscitation for patients with early septic shock. *N Engl J Med*. 2014;371:1496-1506. doi: 10.1056/NEJMoa1404380
25. Weng TI, Huang CH, Ma MH, Chang WT, Liu SC, Wang TD, Chen WJ. Improving the rate of return of spontaneous circulation for out-of-hospital cardiac arrests with a formal, structured emergency resuscitation team. *Resuscitation*. 2004;60:137-142. doi: 10.1016/j.resuscitation.2003.09.007
26. Galpern D, Guerrero A, Tu A, Fahoum B, Wise L. Effectiveness of a central line bundle campaign on line-associated infections in the intensive care unit. *Surgery*. 2008;144:492-495; discussion 495. doi: 10.1016/j.surg.2008.06.004
27. Kjaergaard J, Moller JE, Schmidt H, Grand J, Molstrom S, Borregaard B, Veno S, Sarkisian L, Mamaev D, Jensen LO, et al. Blood-Pressure Targets in Comatose Survivors of Cardiac Arrest. *N Engl J Med*. 2022;387:1456-1466. doi:

- 1            10.1056/NEJMoa2208687
- 2    28.    Schmidt H, Kjaergaard J, Hassager C, Molstrom S, Grand J, Borregaard B,
- 3            Roelsgaard Obling LE, Veno S, Sarkisian L, Mamaev D, et al. Oxygen Targets in
- 4            Comatose Survivors of Cardiac Arrest. *N Engl J Med.* 2022;387:1467-1476. doi:
- 5            10.1056/NEJMoa2208686
- 6

**Table 1. Comparison of patient characteristics between time periods**

	Overall	Period 1 2011-2015	Period 2 2016-2020	<i>p-value</i>
	n = 1192	n = 499	n = 693	
Male Sex (%)	802 (67.3)	325 (65.1)	477 (68.8)	0.189
Age, median(IQR), yr	68 (56-79)	67 (55-79)	68 (57-79)	0.290
Age ≥65 yrs (%)	693 (58.1)	276 (55.3)	417 (60.2)	0.096
<b>Underlying Characteristics</b>				
Hypertension (%)	622 (52.2)	244 (48.9)	378 (54.5)	0.060
Diabetes mellitus (%)	365 (30.6)	155 (31.1)	210 (30.3)	0.799
Hyperlipidemia (%)	112 (9.4)	37 (7.4)	75 (10.8)	0.056
CAD (%)	346 (29.0)	123 (24.6)	223 (32.2)	0.005
Heart failure (%)	118 (9.9)	44 (8.8)	74 (10.7)	0.326
VHD (%)	28 (2.3)	8 (1.6)	20 (2.9)	0.177
Arrhythmia (%)	141 (11.8)	48 (9.6)	93 (13.4)	0.046
COPD/Asthma (%)	100 (8.4)	43 (8.6)	57 (8.2)	0.833
Renal disease (%)	116 (9.7)	53 (10.6)	63 (9.1)	0.428
ESRD (%)	107 (9.0)	40 (8.0)	67 (9.7)	0.356
CVA (%)	104 (8.7)	37 (7.4)	67 (9.7)	0.178
Dementia (%)	50 (4.2)	25 (5.0)	25 (3.6)	0.244
Bedridden (%)	49 (4.1)	14 (2.8)	35 (5.1)	0.056
Malignancy (%)	289 (24.2)	122 (24.4)	167 (24.1)	0.891
<b>Cardiac Arrest Events</b>				
Source (%)				
OHCA	736 (61.7)	285 (57.1)	451 (65.1)	0.017
IHCA	386 (32.4)	179 (35.9)	207 (29.9)	—
Transfer	70 (5.9)	35 (7.0)	35 (5.1)	—
Witnessed collapse (%)	969 (81.3)	391 (78.4)	578 (83.4)	0.029
Initial shockable rhythm (%)	289 (24.2)	99 (19.8)	190 (27.4)	0.003
Bystander CPR (%)	667 (56.0)	246 (49.3)	421 (60.8)	<0.001
Prehospital ROSC (%)	106 (9.6)	39 (8.8)	67 (10.0)	0.533
Adrenaline ≥3 mg (%)	607 (50.9)	275 (55.1)	332 (47.9)	0.016
CPR duration, median(IQR), min	19 (9-33)	18 (9-30)	20 (9-34)	0.129
CPR ≤10 min (%)	338 (29.0)	142 (29.6)	196 (28.6)	0.331
CPR 10-20 min (%)	251 (21.5)	112 (23.3)	139 (20.3)	—
CPR ≥20 min (%)	576 (49.4)	226 (47.1)	350 (51.1)	—
Cardiogenic arrest (%)	591 (49.6)	239 (47.9)	352 (50.8)	0.348
Repeated CPR (%)	409 (34.3)	161 (32.3)	248 (35.8)	0.216
ROSC HR, median(IQR), bpm	105 (79-128)	107 (79-129)	104 (79-129)	0.573
ROSC SBP, median(IQR), mmHg	117 (86-152)	121 (90-159)	116 (85-151)	0.039
sCAHP severity (%)				



Low-Risk	248 (20.8)	105 (21.0)	143 (20.6)	0.002
Medium-Risk	547 (45.9)	255 (51.1)	292 (42.1)	—
High-Risk	397 (33.3)	139 (27.9)	258 (37.2)	—
APACHE II score, median(IQR)	32 (26-37)	28 (24-33)	34 (30-39)	<0.001
<b>Laboratory Exams during CPR</b>				
WBC, median(IQR), K/uL	12.02 (8.94-16.36)	12.28 (9.06-16.69)	11.84 (8.85-16.18)	0.353
Hemoglobin, median(IQR), g/dL	12.3 (10.0-14.6)	12.1 (10.0-14.4)	12.5 (10.0-14.7)	0.284
Platelet, median(IQR), K/uL	190 (139-252)	187 (134-244)	194 (142-257)	0.157
Lactic acid, median(IQR), mmol/L	9.7 (6.5-13.0)	9.3 (6.1-12.7)	9.9 (6.7-13.2)	0.122
pH, median(IQR),	7.11 (6.99-7.23)	7.14 (7.05-7.24)	7.08 (6.95-7.21)	<0.001
HCO <sub>3</sub> , median(IQR), mmol/L	19.0 (15.0-23.6)	19.7 (15.7-24.9)	18.5 (14.6-22.9)	<0.001

Data presented as no. (%) or as median (IQR).

CAD, coronary artery disease; CPR, cardiopulmonary resuscitation; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; ESRD, end-stage renal disease; HR, heart rate; IHCA, in-hospital cardiac arrest; OHCA, out-of-hospital cardiac arrest; ROSC, return of spontaneous circulation; SBP, systolic blood pressure; sCAHP, simplified Cardiac Arrest Hospital Prognosis; VHD, valvular heart disease.

**Table 2. Comparison of post-arrest care between time periods**

	Overall	Period 1 2011-2015	Period 2 2016-2020	<i>p-value</i>
	n = 1192	n = 499 (41.9%)	n = 693 (58.1%)	
ECG after ROSC (%)	1111 (93.2)	458 (91.8)	653 (94.2)	0.103
Echocardiography after ROSC (%)	583 (48.9)	227 (45.5)	356 (51.4)	0.046
Brain CT after ROSC (%)	782 (65.6)	279 (55.9)	503 (72.6)	<0.001
Emergent CAG (%)	250 (21.0)	85 (17.0)	165 (23.5)	0.005
TTM of 33°C (%)	374 (31.4)	142 (28.5)	232 (33.5)	0.067
ROSC to start cooling, median(IQR), hr	4 (2-6)	3 (2-6)	4 (2-6)	0.514
Cooling to target temperature, median(IQR), hr	4 (2-7)	5 (3-9)	3 (2-6)	<0.001
Rewarming duration, median(IQR), hr	14 (12-19)	15 (11-21)	14 (12-18)	0.152
ECMO (%)	226 (19.0)	93 (18.6)	133 (19.2)	0.823
ROSC 3hr				
MAP≥65 mmHg (%)	749 (83.8)	290 (82.4)	459 (84.7)	0.403
inotrope use (%)	751 (63.0)	293 (58.7)	458 (66.1)	0.011
PO2 75-100 mmHg (%)	138 (11.6)	59 (11.8)	79 (11.4)	0.855
PCO2 35-45 mmHg (%)	246 (25.9)	91 (23.5)	155 (27.5)	0.176
Lactic acid change from ROSC, median(IQR), mmol/L	-0.90 (-6.08-5.20)	-0.16 (-5.07-5.46)	-1.64 (-6.33-4.45)	0.067
Decreased Lactic acid from ROSC (%)	264 (55.7)	119 (51.1)	145 (60.2)	0.052
Within 3 days after ROSC				
Fever(≥38.3°C) (%)	208 (17.4)	97 (19.4)	111 (16.0)	0.142
Highest body temperature , median(IQR), °C	37.1 (36.0-38.0)	37.3 (36.0-38.1)	37.0 (36.0-37.9)	0.030
Infection workup (%)	742 (63.0)	297 (61.2)	445 (64.1)	0.327
EEG (%)	223 (18.7)	71 (14.2)	152 (21.9)	0.001
AED use (%)	227 (19.0)	68 (13.6)	159 (22.9)	<0.001

Data presented as no. (%) or as median (IQR).

AED, anti-epileptic drugs; CAG, coronary angiography; CT, computed tomography; ECG, electrocardiogram; ECMO, extracorporeal myocardial oxygenation; EEG, electroencephalogram; MAP, mean arterial pressure; ROSC, return of spontaneous circulation; TTM, targeted temperature management.

**Table 3. Comparison of outcomes between time periods**

	Overall	Period 1 2011-2015	Period 2 2016-2020	OR (95% CI)	aOR† (95% CI)
	n = 1192	n = 499	n = 693		
Active withdrawal (%)	117 (9.8)	34 (6.8)	83 (12.0)	1.86 (1.23-2.83)*	1.84 (1.19-2.83)*
Survival to ICU discharge (%)	386 (32.4)	162 (32.5)	224 (32.3)	0.99 (0.77-1.27)	0.88 (0.67-1.15)
Favorable outcome at ICU discharge (%)	222 (18.6)	66 (13.2)	156 (22.5)	1.91 (1.39-2.61)‡	1.79 (1.27-2.51)*
Survival to hospital discharge (%)	337 (28.3)	144 (28.9)	193 (27.8)	0.95 (0.74-1.23)	0.83 (0.62-1.09)
Favorable outcome at hospital discharge (%)	218 (18.3)	70 (14.0)	148 (21.4)	1.66 (1.22-2.27)*	1.60 (1.14-2.26)*
Cardiac cause of death (%)	286 (24.0)	116 (23.2)	170 (24.5)	1.07 (0.82-1.31)	1.05 (0.79-1.39)
3-month survival (%)	182 (15.3)	75 (15.0)	107 (15.4)	1.03 (0.75-1.42)	0.92 (0.64-1.31)
1-year survival (%)	169 (14.2)	70 (14.0)	99 (14.3)	1.02 (0.73-1.42)	0.87 (0.61-1.26)

Period 1 as reference group, CPC=1-2 was considered favorable neurological outcome

Data presented as no. (%)

† adjusted by age, initial shockable rhythm, witnessed collapse, and CPR duration groups \*p <0.05, ‡p<0.001

aOR, adjusted odds ratio; CI, confidence interval; CPC, cerebral performance category; ICU, intensive care unit.

## Figure Legends

Figure 1. The flowchart of enrolled patients

CPC, Glasgow-Pittsburgh Cerebral Performance Category; ICH, intracranial hemorrhage; ROSC, return of spontaneous circulation; TTM, targeted temperature management.

Figure 2. Comparison of Outcomes between Time Periods


CPC, Glasgow-Pittsburgh Cerebral Performance Category

Figure 3. The benefit of TTM over non-TTM in survival and neurological outcomes


Non-TTM as reference group, CPC=1-2 was considered as favorable neurological recovery


† adjusted by age, initial shockable rhythm, witnessed collapse, and CPR duration groups

aOR, adjusted odds ratio; CI, confidence interval; CPC, cerebral performance category; TTM, targeted temperature management



## Comparison of Outcomes between Time Periods



**(A) Survival****(B) Favorable neurological recovery**